profit from every $100 of sales.
$0$100
Soligenix
$0.32+0.31% today
-76.7% in 1 year
1-year low $0.281-year high $1.65
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Soligenix sold, what it kept, and what it did with the cash.
Sales went from $250,000 in 2022 to $0 in 2025, with -$11.1 million of profit last year.
SalesProfit
Soligenix vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Soligenix | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Soligenix's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| -0 | -1 | -0 | 0 | |
| -14 | -8 | -9 | -12 | |
| -14 | -8 | -9 | -12 | |
| -14 | -6 | -8 | -11 | |
| -76.96 | -12.66 | -4.98 | -2.14 | |
| -120.3% | – | – | – | |
| -5,642.4% | – | – | – | |
| -5,519.3% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 14 | 10 | 9 | 9 |
| Cash | 13 | 8 | 8 | 8 |
| Total debt | 10 | 3 | 1 | 0 |
| Total liabilities | 17 | 7 | 5 | 4 |
| -2 | 3 | 4 | 5 | |
| 0 | 0 | 2 | 5 | |
| -143.7% | -100.8% | -133.5% | -165.6% | |
| 558.5% | -243.4% | -200.7% | -209.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -9 | -8 | -10 | |
| 0 | – | – | 0 | |
| -13 | -9 | -8 | -10 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | 1 |
Valuation
- –
- –
- –
- 1.0×
- 30.0×
- –
- –
- -168.8%
- -183.9%
- 0.0%
Profitability
- -120.3%
- -5,642.4%
- -5,519.3%
- 0.0%
- -322.1%
- -136.8%
- -182.6%
- -117.4%
- -354.3%
- –
Growth
- –
- –
- −22.2%
- –
- +129.9%
Financial health
- -0.2×
- 0.11
- 4.8%
- –
- 1.81
- 1.81
- 0.00
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -0.28 | -0.30 | +6.7% |
| Apr 3, 2026 | 0.32 | -0.27 | +218.5% |
| Nov 7, 2025 | -0.58 | -0.63 | +7.9% |
| Aug 14, 2025 | -0.82 | -0.79 | −3.8% |
| May 9, 2025 | -1.06 | -0.67 | −58.2% |
| Mar 21, 2025 | -1.14 | -0.95 | −20.0% |
| Nov 8, 2024 | -0.78 | -1.09 | +28.4% |
| Aug 9, 2024 | -1.31 | -2.11 | +37.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
61Pass
Philip Fisher
41No pass
Peter Lynch
12No pass
Joel Greenblatt
0No pass
Charlie Munger
37No pass
Terry Smith
33No pass
Questions about Soligenix
Is Soligenix a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Soligenix AI analysis
What does Soligenix do?
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. It is in Biotechnology.
Does Soligenix pay a dividend?
No. Soligenix does not pay a dividend at the moment.
Is Soligenix stock halal?
No. Soligenix does not pass our halal screen: its cash and confirmed interest-bearing investments are 106% of its market value, at or above the 33% limit. How we check
How has Soligenix stock done over the past year?
Down 76.7% over the past twelve months, to $0.32. It traded between $0.28 and $1.65 and is 80.5% below its high.
Who are Soligenix's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Soligenix's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.